文献速递膀胱癌与上尿路尿路上皮癌

BCG治疗后进展为肌层浸润性膀胱癌:新辅助化疗前患者选择的优化

Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
PubMed 文献 · J Urol · 2021-06-29

该回顾性研究纳入2005至2018年801例接受根治性膀胱切除术的cT2-3期肌层浸润性膀胱癌患者,比较BCG治疗后进展(P-MIBC)与原发性(D-MIBC)患者的预后。在未接受新辅助化疗的低危患者中,P-MIBC与更差的病理分期升级和生存相关;但接受新辅助化疗后,P-MIBC与D-MIBC的病理缓解和生存结局相当。

要点

  • P-MIBC在未行新辅助化疗时预后显著差于D-MIBC。
  • 新辅助化疗可消除P-MIBC的不良预后影响。
  • P-MIBC应纳入新辅助化疗风险分层选择体系。

核心结论

  • P-MIBC仅接受根治性膀胱切除术时预后较差,但接受新辅助化疗后病理缓解和生存与D-MIBC相当。

研究设计与样本

  • 回顾性分析2005至2018年801例因cT2-3期肌层浸润性膀胱癌行根治性膀胱切除术的患者。

主要发现

  • 801例中P-MIBC占20.3%,D-MIBC占79.7%。
  • 低危未接受新辅助化疗患者中,P-MIBC病理升级率64.9% vs 42.7%(p=0.004),总生存(p=0.006)和癌症特异性生存(p=0.001)更差。
  • 未接受新辅助化疗患者中,P-MIBC vs D-MIBC中位总生存51.5个月(95%CI 40.0-81.0) vs 85.1个月(95%CI 62.8-96.0),p=0.040;中位癌症特异性生存未达到,p=0.014。
  • 接受新辅助化疗患者中,P-MIBC vs D-MIBC中位总生存90.5个月(95%CI 34.0-不可估计) vs 87.8个月(95%CI 68.7-不可估计),p=0.606;中位癌症特异性生存未达到,p=0.448。

临床怎么用

  • 对于BCG治疗后进展为肌层浸润性膀胱癌的患者,应考虑新辅助化疗以改善预后。
  • 在新辅助化疗风险分层选择中,应将P-MIBC纳入考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Data from the pre-neoadjuvant chemotherapy (NAC) era suggests patients who progress on bacillus Calmette-Guérin (BCG) to muscle-invasive bladder cancer (P-MIBC) exhibit worse outcomes compared to de novo MIBC (D-MIBC). Herein, we investigate whether P-MIBC is an independent poor risk factor in the setting of contemporary NAC use. MATERIALS AND METHODS: A review of patients who underwent radical cystectomy (RC) for cT2-3 MIBC from 2005 to 2018 was performed. Patients were stratified into high risk (lymphovascular invasion, variant histology, hydronephrosis, cT3b) vs low risk (no risk factors) and P-MIBC (≤pT1 treated with at least induction BCG who progressed to ≥cT2) vs D-MIBC. RESULTS: Among 801 patients who underwent RC 20.3% had P-MIBC and 79.7% had D-MIBC. In low-risk patients treated without NAC, P-MIBC was associated with pathological upstaging (64.9% vs 42.7%, p=0.004) and worse overall (OS, p=0.006) and cancer-specific survival (CSS, p=0.001) compared to D-MIBC. P-MIBC status conferred uniformly poor survival outcomes to patients who did not receive NAC compared to D-MIBC without NAC (median OS 51.5 months [95% CI 40.0-81.0] vs 85.1 months [95% CI 62.8-96.0], p=0.040; median CSS not reached, p=0.014). However, P-MIBC status did not remain a negative prognostic factor in the setting of NAC (median OS 90.5 months [95% CI 34.0-not estimable] vs 87.8 months [95% CI 68.7-not estimable], p=0.606; median CSS not reached, p=0.448). CONCLUSIONS: P-MIBC confers a poor prognosis when managed with RC alone. Treatment with NAC results in equivalent pathological response and survival outcomes compared to D-MIBC. P-MIBC should be included in risk-stratified approaches to NAC selection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Hensley PJ, Bree KK, Campbell MT, et al. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021. PMID: 34184926. doi:10.1097/JU.0000000000001943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。